Influence of Concentration and Injection Volume on the Bioavailability of Subcutaneous Growth Hormone: Comparison of Administration by Ordinary Syringe and by Injection Pen-Reference-Cited by-同舟云学术

Influence of Concentration and Injection Volume on the Bioavailability of Subcutaneous Growth Hormone: Comparison of Administration by Ordinary Syringe and by Injection Pen

Published:1991-05 Issue:5 Volume:68 Page:355-359
ISSN:0901-9928
Container-title:Pharmacology & Toxicology
language:en
Short-container-title:

Author:

Blok G. J.,Veen E. A.,Susgaard S.,Larsen F.

Publisher

Wiley

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0773.1991.tb01252.x/fullpdf

Reference16 articles.

1. Daily subcutaneous administration of human growth hormone in growth hormone deficient children;Albertsson-Wikland;Acta paediatr. scand.,1986

2. Simplified growth hormone therapy - First clinical experience with the KabiPen;Albertsson-Wikland;Acta paediatr. scand.,1988

3. Growth hormone secretory rates in children as estimated by deconvolution analysis of 24 h plasma concentration profiles;Albertsson-Wikland;Amer. J. Physiol.,1989

4. Absorption of injected insulin;Binder;Acta pharmacol. et toxicol.,1969

5. Insulin pharmacokinetics;Binder;Diabetes Care,1984

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Broad variability in pharmacokinetics of GH following rhGH injections in children;Growth Hormone & IGF Research;2018-06

2. Management of GH treatment in adult GH deficiency;Best Practice & Research Clinical Endocrinology & Metabolism;2017-02

3. Tratamento da deficiência do hormônio de crescimento (GH) em crianças: comparação entre o uso de canetas versus frascos/seringas para a aplicação do GH;Arquivos Brasileiros de Endocrinologia & Metabologia;2007-10

4. Pharmacokinetics and Pharmacodynamics of a New Formulation of Recombinant Human Growth Hormone Administered by ZomaJet 2 Vision, a New Needle-Free Device, Compared to Subcutaneous Administration Using a Conventional Syringe;The Journal of Clinical Pharmacology;2002-11

5. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men;European Journal of Endocrinology;1998-10-01